An endocrine-disrupting chemical, fenvalerate, induces cell cycle progression and collagen type I expression in human uterine leiomyoma and myometrial cells

Toxicology Letters

Volumn 196, Issue 3, 2010, Pages 133-141

  Gao, Xiaohua ^a   Yu, Linda ^a   Castro, Lysandra ^a   Moore, Alicia B ^a   Hermon, Tonia ^a   Bortner, Carl ^a   Sifre, Maria ^a   Dixon, Darlene ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cell growth; Collagen type I; ECM; Fenvalerate; Leiomyoma; Myometrium

Indexed keywords

COLLAGEN TYPE 1; ESTRADIOL; ESTROGEN RECEPTOR; FENVALERATE; LUCIFERASE; MESSENGER RNA;

APOPTOSIS; ARTICLE; BINDING ASSAY; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL LYSATE; CELL STIMULATION; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; MUSCLE CELL; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UTERUS MYOMA;

APOPTOSIS; BROMODEOXYURIDINE; CELL CYCLE; CELL PROLIFERATION; COLLAGEN TYPE I; ENDOCRINE DISRUPTORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEIOMYOMA; MYOMETRIUM; NITRILES; PYRETHRINS; RECEPTORS, ESTROGEN; RNA, MESSENGER; UTERINE NEOPLASMS;

MAMMALIA;

EID: 77953291873     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.03.004     Document Type: Article

References (46)

1. Al-Hendy A., Lee E.J., Wang H.Q., Copland J.A. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am. J. Obstet. Gynecol. 2004, 191:1621-1631.
2. Arslan A.A., Gold L.I., Mittal K., Suen T.C., Belitskaya-Levy I., Tang M.S., Toniolo P. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum. Reprod. 2005, 20:852-863.
3. Bolger R., Wiese T.E., Ervin K., Nestich S., Checovich W. Rapid screening of environmental chemicals for estrogen receptor binding capacity. Environ. Health Perspect. 1998, 106:551-557.
4. Brahma P.K., Martel K.M., Christman G.M. Future directions in myoma research. Obstet. Gynecol. Clin. North Am. 2006, 33. 199-224, xiii.
5. Chen J., Chen H., Liu R., He J., Song L., Bian Q., Xu L., Zhou J., Xiao H., Dai G., Chang H.C., Wang X. Effects of fenvalerate on progesterone production in cultured rat granulosa cells. Reprod. Toxicol. 2005, 20:195-202.
6. Ding L., Xu J., Luo X., Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J. Clin. Endocrinol. Metab. 2004, 89:5549-5557.
7. Dixon D., Flake G.P., Moore A.B., He H., Haseman J.K., Risinger J.I., Lancaster J.M., Berchuck A., Barrett J.C., Robboy S.J. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002, 441:53-62.
8. Ellerington M.C., Whitcroft S.I.J., Whitehead M.I. HRT: developments in therapy. Br. Med. Bull. 1992, 48:401-425.
9. Flake G.P., Andersen J., Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ. Health Perspect. 2003, 111:1037-1054.
10. Garey J., Wolff M.S. Estrogenic and antiprogestagenic activities of pyrethroid insecticides. Biochem. Biophys. Res. Commun. 1998, 251:855-859.
11. Go V., Garey J., Wolff M.S., Pogo B.G. Estrogenic potential of certain pyrethroid compounds in the MCF-7 human breast carcinoma cell line. Environ. Health Perspect. 1999, 107:173-177.
12. Hermon T.L., Moore A.B., Yu L., Kissling G.E., Castora F.J., Dixon D. Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Arch. 2008, 453:557-569.
13. Hodges L.C., Bergerson J.S., Hunter D.S., Walker C.L. Estrogenic effects of organochlorine pesticides on uterine leiomyoma cells in vitro. Toxicol. Sci. 2000, 54:355-364.
14. Houston K.D., Hunter D.S., Hodges L.C., Walker C.L. Uterine leiomyomas: mechanisms of tumorigenesis. Toxicol. Pathol. 2001, 29:100-104.
15. Howe S.R., Gottardis M.M., Everitt J.I., Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995, 136:4996-5003.
16. Hunter D.S., Hodges L.C., Eagon P.K., Vonier P.M., Fuchs-Young R., Bergerson J.S., Walker C.L. Influence of exogenous estrogen receptor ligands on uterine leiomyoma: evidence from an in vitro/in vivo animal model for uterine fibroids. Environ. Health Perspect. 2000, 108(Suppl. 5):829-834.
17. Kasat K., Go V., Pogo B.G. Effects of pyrethroid insecticides and estrogen on WNT10B proto-oncogene expression. Environ. Int. 2002, 28:429-432.
18. Kunimatsu T., Yamada T., Ose K., Sunami O., Kamita Y., Okuno Y., Seki T., Nakatsuka I. Lack of (anti-) androgenic or estrogenic effects of three pyrethroids (esfenvalerate, fenvalerate, and permethrin) in the Hershberger and uterotrophic assays. Regul. Toxicol. Pharmacol. 2002, 35:227-237.
19. Lee T.K., Lee D.K., Kim D.I., Lee Y.C., Chang Y.C., Kim C.H. Inhibitory effects of Scutellaria barbata D. Don on human uterine leiomyomal smooth muscle cell proliferation through cell cycle analysis. Int. Immunopharmacol. 2004, 4:447-454.
20. Leiser A.L., Anderson S.E., Nonaka D., Chuai S., Olshen A.B., Chi D.S., Soslow R.A. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol. Oncol. 2006, 101:86-91.
21. Moniz A.C., Cruz-Casallas P.E., Oliveira C.A., Lucisano A., Florio J.C., Nicolau A.A., Spinosa H.S., Bernardi M.M. Perinatal fenvalerate exposure: behavioral and endocrinology changes in male rats. Neurotoxicol. Teratol. 1999, 21:611-618.
22. Moore A.B., Castro L., Yu L., Zheng X., Di X., Sifre M.I., Kissling G.E., Newbold R.R., Bortner C.D., Dixon D. Stimulatory and inhibitory effects of genistein on human uterine leiomyoma cell proliferation are influenced by the concentration. Hum. Reprod. 2007, 22:2623-2631.
23. Nierth-Simpson E.N., Martin M.M., Chiang T.C., Melnik L.I., Rhodes L.V., Muir S.E., Burow M.E., McLachlan J.A. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology 2009, 150:2436-2445.
24. Ohara N. Sex steroidal modulation of collagen metabolism in uterine leiomyomas. Clin. Exp. Obstet. Gynecol. 2009, 36:10-11.
25. Oliveira C.A., Nie R., Carnes K., Franca L.R., Prins G.S., Saunders P.T., Hess R.A. The antiestrogen ICI 182,780 decreases the expression of estrogen receptor-alpha but has no effect on estrogen receptor-beta and androgen receptor in rat efferent ductules. Reprod. Biol. Endocrinol. 2003, 1:75.
26. Ramachandran S., Kwon K.Y., Shin S.J., Kwon S.H., Cha S.D., Bae I., Cho C.H. Cyclin-dependent kinase inhibitor p27Kip1 controls growth and cell cycle progression in human uterine leiomyoma. J. Korean Med. Sci. 2008, 23:667-673.
27. Romagnolo B., Molina T., Leroy G., Blin C., Porteux A., Thomasset M., Vandewalle A., Kahn A., Perret C. Estradiol-dependent uterine leiomyomas in transgenic mice. J. Clin. Invest. 1996, 98:777-784.
28. Saito K., Tomigahara Y., Ohe N., Isobe N., Nakatsuka I., Kaneko H. Lack of significant estrogenic or antiestrogenic activity of pyrethroid insecticides in three in vitro assays based on classic estrogen receptor alpha-mediated mechanisms. Toxicol. Sci. 2000, 57:54-60.
29. Schwartz S.M., Marshall L.M., Baird D.D. Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ. Health Perspect. 2000, 108(Suppl. 5):821-827.
30. Sener A.B., Seckin N.C., Ozmen S., Gokmen O., Dogu N., Ekici E. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil. Steril. 1996, 65:354-357.
31. Sozen I., Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil. Steril. 2002, 78:1-12.
32. Stewart E.A. Uterine fibroids. Lancet 2001, 357:293-298.
33. Swartz C.D., Afshari C.A., Yu L., Hall K.E., Dixon D. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol. Hum. Reprod. 2005, 11:441-450.
34. Tremblay G.B., Tremblay A., Labrie F., Giguere V. Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res. 1998, 58:877-881.
35. Wakeling A.E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr. Relat. Cancer 2000, 7:17-28.
36. Walker C.L. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog. Horm. Res. 2002, 57:277-294.
37. Walker C.L., Stewart E.A. Uterine fibroids: the elephant in the room. Science 2005, 308:1589-1592.
38. Whitcroft S.I., Stevenson J.C. Hormone replacement therapy: risks and benefits. Clin. Endocrinol. (Oxf.) 1992, 36:15-20.
39. WHO, 1990. Fenvalerate. Environmental Health Criteria 95, WHO, Geneva.
40. WHO, 1996. Fenvalerate. WHO/FAO DATA Sheets on Pesticides No. 90.
41. Wolanska M., Sobolewski K., Drozdzewicz M., Bankowski E. Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth. Mol. Cell. Biochem. 1998, 189:145-152.
42. Wolansky M.J., Harrill J.A. Neurobehavioral toxicology of pyrethroid insecticides in adult animals: a critical review. Neurotoxicol. Teratol. 2008, 30:55-78.
43. Xia Y., Bian Q., Xu L., Cheng S., Song L., Liu J., Wu W., Wang S., Wang X. Genotoxic effects on human spermatozoa among pesticide factory workers exposed to fenvalerate. Toxicology 2004, 203:49-60.
44. Xiao H., Zhang X.C., Zhang L., Dai X.Q., Gong W., Cheng J., Gao R., Wang X. Fenvalerate modifies T-type Ca2+ channels in mouse spermatogenic cells. Reprod. Toxicol. 2006, 21:48-53.
45. Yu L., Saile K., Swartz C.D., He H., Zheng X., Kissling G.E., Di X., Lucas S., Robboy S.J., Dixon D. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol. Med. 2008, 14:264-275.
46. Zbucka M., Miltyk W., Bielawski T., Surazynski A., Palka J., Wolczynski S. Mechanism of collagen biosynthesis up-regulation in cultured leiomyoma cells. Folia Histochem. Cytobiol. 2007, 45(Suppl. 1):S181-S185.